Myelodysplastic Syndrome (MDS) Drugs Market Research Report - Global Forecast till 2027

Myelodysplastic Syndrome (MDS) Drugs Market Research Report: Information by Drug Type (Chemotherapy, Immunomodulatory Drugs), Type of Syndrome (Refractory Cytopenia with Multilineage Dysplasia, Refractory Anemia, Refractory Anemia with Excess Blasts, Refractory Anemia with Ringed Sideroblasts, Refractory Cytopenia with Multilineage Dysplasia), Route of Administration (Oral, Parenteral), End-User (Hospitals, Clinics, Ambulatory Surgical Centers) and Region - Global Forecast till 2027

ID: MRFR/HC/6662-HCR | February 2021 | Region: Global | 90 pages

Myelodysplastic Syndrome (MDS) Drugs Market Scenario

The myelodysplastic syndrome (MDS) drugs market is expected to grow significantly over the forecast period. It is anticipated that the market held a value of USD 1,581.59 million in 2018 and is projected to register a CAGR of 10.1% over the forecast period.

The increasing participation of key players is one of the key factors driving the Myelodysplastic Syndrome (MDS) drugs market. In 2018, the US Food and Drug Administration approved a generic injectable product, decitabine for Lupin Ltd. There are various other MDS medications available in the market.

Various other factors such as the promotion of clinical studies related to MS, increasing geriatric population, rise in regulatory approvals, and growing participation of generic drug manufacturers are boosting the market growth.

However, the risk of infections during blood transfusions and side-effects of chemotherapy may hamper market growth over the forecast period.

Segmentation

The myelodysplastic syndrome (MDS) drugs market is segmented based on type, type of syndrome, route of administration, end user, and region.

Based on type, the myelodysplastic syndrome (MDS) drugs market is further segmented into chemotherapy, immunomodulatory drugs, and others. The chemotherapy segment is sub-segmented as conventional drugs and hypomethylating drugs. Hypomethylating drugs include Azacitidine and Decitabine. Conventional drugs comprise Cytarabine, Daunorubicin, and Idarubicin.

Based on the type of syndrome, the MDS drugs market at the global level is segmented into refractory cytopenia with multilineage dysplasia, refractory anemia, refractory anemia with excess blasts, refractory anemia with ringed sideroblasts, refractory cytopenia with multilineage dysplasia, and others.

Based on the route of administration, the market is segmented into oral, parenteral, and others.

Based on end user, the market is segmented into hospitals, clinics, ambulatory surgical centers, and others.

The segments mentioned above are covered into four global regions, namely, the Americas, Europe, Asia-Pacific, and the Middle East and Africa.

The myelodysplastic syndrome (MDS) drugs market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.

The European Myelodysplastic Syndrome (MDS) drugs market has been segmented into Western Europe and Eastern Europe. Western Europe has been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. The Myelodysplastic Syndrome (MDS) drugs market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The myelodysplastic syndrome drugs market in the Middle East & Africa has been segmented into the Middle East and Africa.

Key Players

BluePoint Laboratories

Celgene Corporation

Celgene Europe Limited

Reddy's Laboratories, Inc.

Johnson & Johnson

Lupin Ltd Corporation

Otsuka America Pharmaceutical Inc.

Sandoz

Shilpa Medicare Limited

Sun Pharmaceutical Industries Inc.

Regional Market Summary

Myelodysplastic syndrome (MDS) drugs market Share (%), by Region, 2018

Sources: MRFR Analysis

The Americas dominated the global MDS drugs market, owing to the increasing number of patients detected with MDS yearly. According to the statistics published by the American Society of Clinical Oncology in 2019, around 10,000 patients are detected with MDS in the US yearly.

In the European region, various studies have been performed to study the prevalence of MDS across different age groups. For instance, the National Institutes of Health conducted a successive study among children with MDS for 15 years. Under the study, 426 children were investigated for Germline GATA-2 mutations and primary MDS. The studies revealed that Germline GATA-2 mutations highly prevailed in patients with monosomy 7 type of mutation. Thus, the European region has a potential scope for the MDS drugs market.

Asia-Pacific is expected to grow owing to the rising research and development activities in this region. The study of clinical features is very important before proceeding for treatment methodology for a patient. As per the study published in the Leukemia Journal in 2018, the difference in clinical features among the Japanese and Caucasian patients with myelodysplastic syndromes was noticed. The study revealed that; chronic lymphocytic leukemia is more frequent in the Caucasians population than the Japanese population. This could be due to susceptibility specific location of the genome. Thus, the MDS drugs market in APAC is predicted to gain the third-largest market share.

The Middle East and Africa held the least share in the myelodysplastic syndrome (MDS) drugs market due to low economic development, especially within the African region.

Intended Audience

Pharmaceutical companies

Government and private laboratories

Research and development (R&D) companies

Research laboratories

Market research and consulting service providers

Market Segmentation

Myelodysplastic syndrome (MDS) drugs market, by Type

Chemotherapy

Hypomethylating Drugs

Azacitidine

Decitabine

Conventional drugs

Cytarabine

Daunorubicin

Idarubicin

Immunomodulatory Drugs

Lenalidomide

Thalidomide

Others

Myelodysplastic syndrome (MDS) drugs market, by Type of Syndrome

Refractory Anemia

Refractory Anemia with Ringed Sideroblasts

Refractory Anemia with Excess Blasts

Refractory Cytopenia with Multilineage Dysplasia

Others

Myelodysplastic syndrome (MDS) drugs market, by Route of Administration

Oral

Parenteral

Others

Myelodysplastic syndrome (MDS) drugs market, by End User

Hospitals

Clinics

Ambulatory Surgical Centers

Others

Report Scope:

Report Attribute/Metric	Details
Market Size	2025: Significant Value
CAGR	10.1% (2019-2025)
Base Year	2019
Forecast Period	2027
Historical Data	2018
Forecast Units	Value (USD Million)
Report Coverage	Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
Segments Covered	Drug Type, Type of Syndrome, End-User
Geographies Covered	North America, Europe, Asia-Pacific, and Rest of the World (RoW)
Key Vendors	BluePoint Laboratories, Celgene Corporation, Celgene Europe Limited, Dr. Reddy's Laboratories Inc., Johnson & Johnson, Lupin Ltd Corporation, Otsuka America Pharmaceutical Inc, Sandoz, Shilpa Medicare Limited, Sun Pharmaceutical Industries Inc
Key Market Opportunities	The increasing participation of key players is one of the key factors
Key Market Drivers	Increasing Geriatric Population. rise in regulatory approvals. growing participation of generic drug manufacturers

Speak to Analyst Ask for Customization

Frequently Asked Questions (FAQ) :

What is the predicted CAGR for the Myelodysplastic Syndrome (MDS) drugs market during the forecast period of 2019 to 2025?

Myelodysplastic Syndrome (MDS) drugs market would record a CAGR of 10.1% during the forecast period of 2019-2025.

How big the Myelodysplastic Syndrome (MDS) drugs market was in 2018?

Myelodysplastic Syndrome (MDS) drugs market had a valuation of USD 1581.59 million in 2018.

What could hold back the Myelodysplastic Syndrome (MDS) drug market growth?

The risk of infection with blood transfusion and chemotherapy’s side-effects can hold back the growth of the Myelodysplastic Syndrome (MDS) drugs market.

What are the routes of administrations discussed for the Myelodysplastic Syndrome (MDS) drugs market?

Myelodysplastic Syndrome (MDS) drugs market report includes a discussion of oral, parenteral, and others.

Which region would enjoy the lead of the Myelodysplastic Syndrome (MDS) drug market?

The Americas would hold the Myelodysplastic Syndrome (MDS) drugs market lead.

Table of Contents

Chapter 1. Executive Summary

Chapter 2. Market Introduction

2.1 Definition

2.2 Scope of the Study

2.3 Assumptions

2.4 Limitations

Chapter 3. Research Methodology

3.1 Research Process

3.2 Primary Research

3.3 Secondary Research

3.4 Market Size Estimation

3.5 Forecast Model

Chapter 4. Market Dynamics

4.1 Overview

4.2 Drivers

4.3 Restraints

4.4 Opportunities

4.5 Pipeline Analysis

4.5 Macroeconomic Indicators

Chapter 5. Market Factor Analysis

5.1 Porter’s Five Forces Analysis

5.1.1 Bargaining Power of Suppliers

5.1.2 Bargaining Power of Buyers

5.1.3 Threat of New Entrants

5.1.4 Threat of Substitutes

5.1.5 Intensity of Rivalry

5.2 Value Chain Analysis

5.3 Investment Opportunities

Chapter 6. Global Myelodysplastic Syndrome (MDS) Drugs Market, by Type

6.1 Overview

6.2 Chemotherapy

6.2.1 Hypomethylating Drugs

6.2.1.1 Azacitidine

Market Estimates & Forecast, by Region, 2020-2027